CareDx Secures Dismissal of 2021 Qui Tam Suit Without Penalty

Event summary

  • CareDx's 2021 qui tam lawsuit was dismissed on April 23, 2026, with no monetary payment required.
  • The dismissal followed the plaintiff's request and the DOJ's concurrence.
  • The DOJ concluded its investigation in October 2024, finding no wrongdoing by CareDx.
  • The initial lawsuit was filed on February 12, 2021, triggering a DOJ investigation.

The big picture

The dismissal of the qui tam suit removes a significant legal overhang for CareDx, allowing the company to refocus on its precision medicine offerings for transplant patients. The resolution underscores the importance of regulatory compliance in the healthcare sector, particularly for companies operating in high-stakes areas like organ transplants. The case also highlights the growing scrutiny of precision medicine firms by regulators, a trend likely to continue as the industry expands.

What we're watching

Legal Risk
How the dismissal affects CareDx's legal exposure in other ongoing or potential litigation.
Regulatory Scrutiny
Whether the DOJ's decision signals reduced regulatory risk for precision medicine companies.
Operational Focus
The pace at which CareDx can shift resources from legal defense to core business growth.